Loading...
XASXIPD
Market cap66mUSD
Jan 07, Last price  
0.05AUD
1D
1.92%
1Q
-8.62%
Jan 2017
-94.80%
IPO
-93.70%
Name

ImpediMed Ltd

Chart & Performance

D1W1MN
XASX:IPD chart
P/E
—
P/S
10.40
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
38.45%
Rev. gr., 5y
19.95%
Revenues
10m
-9.04%
02,311,3992,991,9533,639,0003,887,0002,945,0002,733,0003,521,0004,844,0005,791,0005,766,0003,318,0004,155,9995,741,0008,409,00010,566,00011,344,00010,319,000
Net income
-20m
L-3.56%
0-9,754,128-14,027,655-11,402,000-14,822,000-12,342,000-8,464,000-7,935,000-14,797,000-25,980,000-27,571,000-27,248,000-23,996,000-21,377,000-20,706,000-19,874,000-20,521,000-19,790,000
CFO
-18m
L-1.44%
0-7,416,381-11,786,199-10,386,000-11,299,000-11,797,000-7,675,000-6,802,000-10,757,000-22,422,000-25,566,000-23,458,000-19,588,000-19,218,000-13,258,000-15,664,000-18,049,000-17,789,000
Earnings
Feb 25, 2025

Profile

ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
URL
https://www.impedimed.com
IPO date
Oct 24, 2007
Employees
76
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
10,319
-9.04%
11,344
7.36%
10,566
25.65%
Cost of revenue
24,154
31,379
30,118
Unusual Expense (Income)
NOPBT
(13,835)
(20,035)
(19,552)
NOPBT Margin
Operating Taxes
(935)
(1,555)
(1,573)
Tax Rate
NOPAT
(12,900)
(18,480)
(17,979)
Net income
(19,790)
-3.56%
(20,521)
3.26%
(19,874)
-4.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
(66)
26,990
38,077
BB yield
0.05%
-8.33%
-37.18%
Debt
Debt current
333
141
170
Long-term debt
1,953
2,294
170
Deferred revenue
695
422
360
Other long-term liabilities
81
442
53
Net debt
(22,400)
(43,353)
(40,645)
Cash flow
Cash from operating activities
(17,789)
(18,049)
(15,664)
CAPEX
(81)
(6,043)
(5,221)
Cash from investing activities
(3,105)
(6,043)
(5,221)
Cash from financing activities
(481)
27,932
39,917
FCF
(12,220)
(20,692)
(17,367)
Balance
Cash
24,632
45,710
40,730
Long term investments
54
78
255
Excess cash
24,170
45,221
40,457
Stockholders' equity
40,743
60,879
51,044
Invested Capital
18,492
17,969
11,170
ROIC
ROCE
EV
Common stock shares outstanding
2,021,741
1,800,349
1,678,954
Price
0.07
-60.00%
0.18
195.08%
0.06
-41.90%
Market cap
145,565
-55.08%
324,063
216.42%
102,416
-18.87%
EV
123,165
280,710
61,771
EBITDA
(11,582)
(17,568)
(16,783)
EV/EBITDA
Interest
93
34
28
Interest/NOPBT